Courage Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Courage Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,050	Closed	-$231K	–	35
2021 Q4	$231K	Hold	3,050	–	–	0.15%	38
2021 Q3	$341K	Hold	3,050	–	–	0.18%	37
2021 Q2	$494K	Hold	3,050	–	–	0.3%	33
2021 Q1	$372K	Hold	3,050	–	–	0.27%	34
2020 Q4	$467K	Sell	3,050 -750	-20%	-$88.6K	0.47%	26
2020 Q3	$318K	Hold	3,800	–	–	0.36%	30
2020 Q2	$279K	Buy	+3,800	New	+$222K	0.51%	23
2020 Q1	–	Sell	-3,800	Closed	-$231K	–	27
2019 Q4	$231K	Buy	+3,800	New	+$207K	0.7%	12
2018 Q3	–	Sell	-7,200	Closed	-$423K	–	26
2018 Q2	$423K	Sell	7,200 -900	-11%	-$51.3K	0.32%	19
2018 Q1	$370K	Hold	8,100	–	–	0.28%	22
2017 Q4	$190K	Buy	+8,100	New	+$154K	0.14%	22

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Courage Capital Management's CRSP Position: Q1 2022 in Review

Courage Capital Management sold out of CRISPR Therapeutics (CRSP) in Q1 2022, closing a stake of 3,050 shares — an estimated $231K sold.

Courage Capital Management first reported a position in CRSP in Q4 2017 and held it in 11 quarters. The position peaked at $494K in Q2 2021. 447 funds tracked by Wall St. Rank hold CRSP as of Q1 2022.

Courage Capital Management reported no remaining CRISPR Therapeutics position as of Q1 2022 after selling out during the quarter.
Courage Capital Management sold 3,050 CRISPR Therapeutics shares in Q1 2022, an estimated $231K.
Courage Capital Management first reported a position in CRISPR Therapeutics in Q4 2017 and held it in 11 quarters.
Courage Capital Management's CRISPR Therapeutics position peaked at $494K in Q2 2021.
447 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2022.

Based on Courage Capital Management's 13F filing for Q1 2022, filed 16 May 2022.